Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023

Rhea-AI Summary

Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its first quarter 2023 financial results on May 5, 2023, before the market opens. The company will hold a conference call at 8:30 AM ET to discuss these results and address questions from investors. Fulgent operates in two primary sectors: a clinical diagnostic business providing molecular and genetic testing, and a therapeutic development segment focused on cancer treatment through innovative drug delivery methods. The company aims to transition from a genomic diagnostics provider to a fully integrated precision medicine firm.

Positive

• Fulgent's shifting focus towards precision medicine could enhance long-term growth opportunities.
• The scheduled conference call indicates transparency and engagement with investors.

Negative

• None.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

About Fulgent

Fulgent is a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent’s clinical diagnostic business offers molecular diagnostic testing services, comprehensive genetic testing, and high-quality anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005846/en/

Investor Relations Contact:

The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When will Fulgent Genetics release its Q1 2023 financial results?

Fulgent Genetics will release its Q1 2023 financial results on May 5, 2023, before the market opens.

What time is the Fulgent Genetics conference call?

The conference call for Fulgent Genetics is scheduled for 8:30 AM ET on May 5, 2023.

How can I access the Fulgent Genetics conference call?

You can access the conference call through a live audio webcast on the Investor Relations section of Fulgent's website.

What are the main business focuses of Fulgent Genetics?

Fulgent Genetics focuses on clinical diagnostics and therapeutic development, particularly in cancer treatment.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades under the stock symbol FLGT on NASDAQ.